Clinical Research Directory
Browse clinical research sites, groups, and studies.
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
Sponsor: Dana-Farber Cancer Institute
Summary
This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
1000
Start Date
2025-04-01
Completion Date
2030-09-01
Last Updated
2025-12-10
Healthy Volunteers
Yes
Conditions
Interventions
Circulating Tumor DNA (ctDNA) Assay
Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months.
Locations (6)
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute at Steward St. Elizabeth's
Brighton, Massachusetts, United States
Dana-Farber Cancer Instiute Merrimack Valley
Methuen, Massachusetts, United States
Dana-Farber Cancer Institute South Shore
South Weymouth, Massachusetts, United States